

USA Market Outlook - 16 August 2021

Despite the Dow and the S&P 500 both rising to new record highs early in the session, U.S. stocks closed the day fairly flat.

The Dow completed the afternoon at 35,515.38, up 15.53 points or 0.04 percent, after rising to 35,610.57 in early sessions. The S&P 500 gained 7.17 points (0.16 percent) to 4,468.00, while the Nasdaq gained 6.64 points (0.04 percent) to 14,822.90.

Apple Inc.'s stock increased by more than 2%. Microsoft and Tesla both increased by around 1% and 2%, respectively.

The value of Walt Disney's stock increased by more than 6%.

Merck, Cisco Systems, Johnson & Johnson, and United Health all ended the day in the black, though with smaller gains.

Salesforce.com has risen as a result of its positive performance. Microsoft, Netflix, Comcast, and WPP all ended the day with gains.

Core producer prices increased by 0.9 percent in July after growing by 0.5 percent in June, excluding food, energy, and trade services.

The Labor Department reported on Tuesday that worker productivity growth slowed in the second quarter, and labour expenses were significantly lower than originally predicted in the first quarter.

Initial jobless claims fell to 375,000 in the week ending August 7th, down 12,000 from the previous week's revised total of 387,000, according to the Labor Department.

In the second quarter of this year, the United States' gross domestic product increased 12.2% over the same period last year, beating China's 7.9% increase.

The sharp drop coincides with the fast spread of the delta version of Covid-19 across the United States, prompting several states and towns to reintroduce mask laws and other health restrictions.

According to the University of Michigan's Surveys of Consumers, consumer sentiment fell to 70.2 in early August from 81.2 in July.

This is the lowest reading since 2011 and the worst one-month dip since the pandemic began, when confidence vanished.

As of Saturday morning, the United States had administered 355,768,825 doses of COVID-19 vaccine and distributed 415,915,655 doses, according to the US CDC.

Top Gainers

Name	Last Price	%Change
eBay Inc.	\$74.02	7.45%
Advanced Micro Devices Inc.	\$110.55	3.80%
Regeneron Pharmaceuticals Inc.	\$624.79	2.76%
Pfizer Inc.	\$48.48	2.62%
Tyson Foods Inc. Cl A	\$81.91	2.34%

Top Losers

Name	Last Price	%Change
APA Corp.	\$17.88	-5.50%
Diamondback Energy Inc.	\$75.64	-4.70%
HP Inc.	\$29.01	-4.57%
Occidental Petroleum Corp.	\$25.79	-4.02%
Gap Inc.	\$28.89	-3.70%

USA Market Outlook - 16 August 2021

Disclaimer and General Advice Instructions:

This document is provided by Laverne Securities Pty Ltd T/as La Verne Investing the Corporate Authorized Representative No. CAR No. 001269781 of La Verne Capital Pty Ltd AFSL 482937. The Research Analyst who prepared this report/article hereby certifies that the views expressed in this document accurately reflect the analyst's personal views about the Company and its financial products. The information provided in the Report/Article is provided by Morningstar and FactSet. La Verne Fund is not a fund manager, however, the portfolio and the document is for general advice only, prepared by the Analysts and Research team for our clients.

This report/article have Different Assumptions, Views, Analytical Method of the analyst with no guarantee of reliability and accuracy of the content. The Research Analyst has not been, is not, and will not be receiving direct or indirect compensation for expressing the specific recommendations or views in this report/article. La Verne Securities has its own Research methodology, with regards to the rating and is confirmed by the team for long term Strategic rating of the concerned security as an Investment for Portfolios with High Growth High Risk Profile. Individual Stock is Speculative and of High Risk in nature and strongly

This Document is provided for the Advisors, their Clients, and Financial Professionals for information only and should not be considered an offer or solicitation of an offer to buy or sell a particular security or financial product or instrument.

The information or services provided in this report/article may not be suitable for you and we strongly recommend taking the advice of your Financial Planner or Investment advisors. Laverne Investing will not treat the recipients as its customer by virtue of their receiving the report/article and should seek the advice of their consultant, prior to making any investment decision considering this report/article